• Hyperlipoproteinemias

Leqvio Generic Name & Formulations

General Description

Inclisiran 284mg/1.5mL (189mg/mL); per prefilled syringe; soln for SC inj; preservative-free.

Pharmacological Class

Small interfering RNA (siRNA).

How Supplied

Single-dose prefilled syringe—1

Generic Availability


Mechanism of Action

Inclisiran is a double-stranded siRNA, conjugated on the sense strand with triantennary N-Acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisiran utilizes the RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation.

Leqvio Indications


Adjunct to diet and statin therapy in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C.

Leqvio Dosage and Administration


Give by SC inj into abdomen, thigh, or upper arm. Initially 284mg as a single inj, repeat at 3 months, and then every 6 months. Measure LDL-lowering effect as early as 30 days after initiation and anytime thereafter.


Not established.

Leqvio Contraindications

Not Applicable

Leqvio Boxed Warnings

Not Applicable

Leqvio Warnings/Precautions


Do not inject into areas of active skin disease or injury (eg, sunburns, skin rashes, inflammation, skin infections). ESRD. Severe hepatic impairment. Pregnancy: avoid. Nursing mothers.

Leqvio Pharmacokinetics


Plasma protein bound: 87%. Apparent volume of distribution: ~500 L.


Primarily by nucleases. 


Renal (~16%). Half-life: ~9 hours.

Leqvio Interactions

Not Applicable

Leqvio Adverse Reactions

Adverse Reactions

Inj site reaction, arthralgia, bronchitis.

Leqvio Clinical Trials

See Literature

Leqvio Note

Not Applicable

Leqvio Patient Counseling

See Literature